Competition NMR for Detection of Hit/Lead Inhibitors of Protein-Protein Interactions

被引:13
作者
Musielak, Bogdan [1 ]
Janczyk, Weronika [2 ]
Rodriguez, Ismael [1 ]
Plewka, Jacek [1 ]
Sala, Dominik [1 ]
Magiera-Mularz, Katarzyna [1 ]
Holak, Tad [1 ,2 ]
机构
[1] Jagiellonian Univ, Dept Organ Chem, Fac Chem, Gronostajowa 2, PL-30387 Krakow, Poland
[2] Max Planck Inst Biochem, Klopferspitz 18, D-82152 Martinsried, Germany
关键词
NMR; Mdm2; p53; PD-1; PD-L1; protein-protein interaction; small molecule; CANCER-IMMUNOTHERAPY; LIGAND-BINDING; DRUG DISCOVERY; DEATH; P53; MDM2; ANTAGONISTS; DESIGN; PD-1; SAR;
D O I
10.3390/molecules25133017
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Screening for small-molecule fragments that can lead to potent inhibitors of protein-protein interactions (PPIs) is often a laborious step as the fragments cannot dissociate the targeted PPI due to their low mu M-mM affinities. Here, we describe an NMR competition assay called w-AIDA-NMR (weak-antagonist induced dissociation assay-NMR), which is sensitive to weak mu M-mM ligand-protein interactions and which can be used in initial fragment screening campaigns. By introducing point mutations in the complex's protein that is not targeted by the inhibitor, we lower the effective affinity of the complex, allowing for short fragments to dissociate the complex. We illustrate the method with the compounds that block the Mdm2/X-p53 and PD-1/PD-L1 oncogenic interactions. Targeting the PD-/PD-L1 PPI has profoundly advanced the treatment of different types of cancers.
引用
收藏
页数:16
相关论文
共 67 条
[1]   A Nobel Prize-worthy pursuit: cancer immunology and harnessing immunity to tumour neoantigens [J].
Altmann, Daniel M. .
IMMUNOLOGY, 2018, 155 (03) :283-284
[2]   Deconstructing fragment-based inhibitor discovery [J].
Babaoglu, Kerim ;
Shoichet, Brian K. .
NATURE CHEMICAL BIOLOGY, 2006, 2 (12) :720-723
[3]   NMR-Based Approaches for the Identification and Optimization of Inhibitors of Protein-Protein Interactions [J].
Barile, Elisa ;
Pellecchia, Maurizio .
CHEMICAL REVIEWS, 2014, 114 (09) :4749-4763
[4]   Robust NMR Screening for Lead Compounds Using Tryptophan-Containing Proteins [J].
Bista, Michal ;
Kowalska, Kaja ;
Janczyk, Weronika ;
Doemling, Alexander ;
Holak, Tad A. .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2009, 131 (22) :7500-+
[5]   Awakening guardian angels: drugging the p53 pathway [J].
Brown, Christopher J. ;
Lain, Sonia ;
Verma, Chandra S. ;
Fersht, Alan R. ;
Lane, David P. .
NATURE REVIEWS CANCER, 2009, 9 (12) :862-873
[6]   Targeting apoptosis in cancer therapy [J].
Carneiro, Benedito A. ;
El-Deiry, Wafik S. .
NATURE REVIEWS CLINICAL ONCOLOGY, 2020, 17 (07) :395-417
[7]   Evolutions in fragment-based drug design: the deconstruction-reconstruction approach [J].
Chen, Haijun ;
Zhou, Xiaobin ;
Wang, Ailan ;
Zheng, Yunquan ;
Gao, Yu ;
Zhou, Jia .
DRUG DISCOVERY TODAY, 2015, 20 (01) :105-113
[8]   Structure and Interactions of the Human Programmed Cell Death 1 Receptor [J].
Cheng, Xiaoxiao ;
Veverka, Vaclav ;
Radhakrishnan, Anand ;
Waters, Lorna C. ;
Muskett, Frederick W. ;
Morgan, Sara H. ;
Huo, Jiandong ;
Yu, Chao ;
Evans, Edward J. ;
Leslie, Alasdair J. ;
Griffiths, Meryn ;
Stubberfield, Colin ;
Griffin, Robert ;
Henry, Alistair J. ;
Jansson, Andreas ;
Ladbury, John E. ;
Ikemizu, Shinji ;
Carr, Mark D. ;
Davis, Simon J. .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2013, 288 (17) :11771-11785
[9]   Translating p53 into the clinic [J].
Cheok, Chit Fang ;
Verma, Chandra S. ;
Baselga, Jose ;
Lane, David P. .
NATURE REVIEWS CLINICAL ONCOLOGY, 2011, 8 (01) :25-37
[10]  
Chupak L.S., 2015, Patent No. [WO/2015/03, 201503]